Edgewise Therapeutics (EWTX) director granted 16,377 stock options at $35.59
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Edgewise Therapeutics director Laura Brege received a new stock option grant covering 16,377 shares of common stock. The options have an exercise price of $35.59 per share and expire on June 5, 2036. According to the grant terms, 100% of the options vest on the earlier of June 5, 2027 or the business day before the 2027 annual meeting of stockholders.
After this grant, Brege holds 16,377 stock options directly, all tied to this award.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Brege Laura
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 16,377 | $0.00 | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 16,377 shares (Direct, null)
Footnotes (1)
- [object Object]
Key Figures
Option grant size: 16,377 shares
Exercise price: $35.59 per share
Expiration date: June 5, 2036
+2 more
5 metrics
Option grant size
16,377 shares
Stock Option (Right to Buy) granted June 5, 2026
Exercise price
$35.59 per share
Exercise price for the stock option grant
Expiration date
June 5, 2036
Option expiration date
Vesting date trigger
June 5, 2027
Earlier of this date or business day before 2027 annual meeting
Options held after grant
16,377 options
Total stock options following this transaction
Key Terms
Stock Option (Right to Buy), exercise price, vested, expiration date, +1 more
5 terms
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
exercise price financial
"conversion_or_exercise_price: 35.5900"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vested financial
"100% of the Stock Options granted on June 5, 2026 will become vested"
expiration date financial
"expiration_date: 2036-06-05T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
underlying security financial
"underlying_security_title: Common Stock"
FAQ
What did Edgewise Therapeutics (EWTX) director Laura Brege report in this Form 4?
Laura Brege reported receiving a stock option grant for 16,377 shares of Edgewise Therapeutics common stock. The options were granted as compensation, have a set exercise price, and will vest in full based on a specified future date or the 2027 annual meeting timing.
What is the exercise price of Laura Brege’s Edgewise Therapeutics stock options?
The stock options granted to Laura Brege have an exercise price of $35.59 per share. This is the fixed price at which she may purchase Edgewise Therapeutics common stock once the options vest and become exercisable under the award terms.
When do Laura Brege’s Edgewise Therapeutics options vest?
All of the options vest 100% on the earlier of June 5, 2027, or the business day before Edgewise Therapeutics’ 2027 annual meeting of stockholders. This single vesting date governs the entire 16,377-share option grant reported in the filing.
When do Laura Brege’s Edgewise Therapeutics stock options expire?
The options granted to Laura Brege expire on June 5, 2036. After that expiration date, any unexercised portion of the 16,377-share option award will no longer be exercisable, according to the terms disclosed in the Form 4 filing.